Loading…
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $184M | $-50M | $-84M | $-111M | -37.0% | 138.8% | -52.2% |
| 2024 | $77M | $-155M | $-175M | $-219M | -62.3% | 32386.9% | -5.2% |
| 2023 | $0M | $-175M | $-184M | $-169M | -74.3% | -60.2% | 29.8% |
| 2022 | $1M | $-134M | $-142M | $-128M | -177.4% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0.60 | 0.24 | 76.99 | 183.88 |
| Operating Revenue | - | 0.60 | 0.24 | 89.92 | 223.37 |
| Cost Of Revenue | - | 0 | 0 | 1.26 | 4.74 |
| Gross Profit | - | 0.60 | 0.24 | 75.74 | 179.14 |
| Operating Expense | - | 139.15 | 194.18 | 249.47 | 230.69 |
| Research And Development | - | 95.52 | 125.05 | 103.74 | 71.43 |
| Selling General And Administration | - | 43.63 | 69.14 | 145.73 | 159.26 |
| Total Expenses | - | 139.15 | 194.18 | 250.73 | 235.43 |
| Operating Income | - | -138.55 | -193.94 | -173.73 | -51.55 |
| Total Operating Income As Reported | - | -138.55 | -193.94 | -173.73 | -68.58 |
| EBITDA | - | -134.15 | -174.78 | -154.85 | -49.64 |
| Normalized EBITDA | - | -134.15 | -174.78 | -153.14 | -32.61 |
| EBIT | - | -135.02 | -175.82 | -156.07 | -50.84 |
| Interest Income | - | 2.53 | 18.15 | 19.61 | 18.12 |
| Interest Expense | - | 6.88 | 8.31 | 18.50 | 32.66 |
| Net Interest Income | - | -4.35 | 9.84 | 1.10 | -14.54 |
| Other Non Operating Income Expenses | - | 1 | -0.02 | -0.24 | -0.38 |
| Other Income Expense | - | 1 | -0.02 | -1.94 | -17.41 |
| Interest Income Non Operating | - | 2.53 | 18.15 | 19.61 | 18.12 |
| Interest Expense Non Operating | - | 6.88 | 8.31 | 18.50 | 32.66 |
| Net Non Operating Interest Income Expense | - | -4.35 | 9.84 | 1.10 | -14.54 |
| Pretax Income | - | -141.90 | -184.13 | -174.57 | -83.50 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | -0.01 | -0.02 |
| Net Income Continuous Operations | - | -141.90 | -184.13 | -174.57 | -83.50 |
| Net Income From Continuing And Discontinued Operation | - | -141.90 | -184.13 | -174.57 | -83.50 |
| Net Income From Continuing Operation Net Minority Interest | - | -141.90 | -184.13 | -174.57 | -83.50 |
| Net Income | - | -141.90 | -184.13 | -174.57 | -83.50 |
| Net Income Common Stockholders | - | -141.90 | -184.13 | -174.57 | -83.50 |
| Net Income Including Noncontrolling Interests | - | -141.90 | -184.13 | -174.57 | -83.50 |
| Normalized Income | - | -141.90 | -184.13 | -172.87 | -66.49 |
| Diluted NI Availto Com Stockholders | - | -141.90 | -184.13 | -174.57 | -83.50 |
| Basic Average Shares | - | 380.78 | 570.65 | 646.03 | 666.66 |
| Diluted Average Shares | - | 380.78 | 570.65 | 646.03 | 666.66 |
| Reconciled Depreciation | - | 0.87 | 1.03 | 1.22 | 1.20 |
| Reconciled Cost Of Revenue | - | 0 | 0 | 1.26 | 4.74 |
| Total Unusual Items | - | 0 | 0 | -1.71 | -17.03 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | -1.71 | -17.03 |
| Special Income Charges | - | 0 | 0 | -1.71 | -17.03 |
| Other Special Charges | - | - | - | 1.71 | - |
| Restructuring And Mergern Acquisition | - | - | 0 | 0 | 17.03 |
| General And Administrative Expense | 29.66 | 43.63 | 69.14 | 145.73 | - |
| Other Gand A | 29.66 | 43.63 | 69.14 | 145.73 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Geron Corporationthis co. | GERN | $776M | -9.30 | 3.44 | -37.0% | -16.53 |
| Esperion Therapeutics, Inc. | ESPR | $806M | - | - | 7.5% | 13.94 |
| Lumexa Imaging Holdings, Inc. | LMRI | $792M | -16.81 | 1.35 | -8.0% | 11.96 |
| Eton Pharmaceuticals, Inc. | ETON | $792M | -172.06 | 30.27 | -17.6% | 248.97 |
| Phathom Pharmaceuticals, Inc. | PHAT | $786M |
| - |
| - |
| - |
| - |
| - |
| -3.55 |
| -1.79 |
| 50.5% |
| -5.69 |
| Kura Oncology, Inc. | KURA | $779M | - | 4.47 | -160.0% | - |
| BioAge Labs, Inc. | BIOA | $757M | -9.39 | 2.78 | -29.6% | -7.19 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| Omeros Corporation | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| Peer Median | - | -13.81 | 2.78 | -12.8% | -5.69 | |